Rasagiline is a Medicine belongs to Antiparkinsonian Drugs group whose information about Brand can be referenced from   Book : Martindale    Page : 900   Edition : 37,

  ►   Brandname : Azilect

  ►  Strength : Tablet with 0.5  mg, Tablet with 1  mg,

Reference of this Medicine for its Strength can be taken from   Book : Basic & Clinical pharmacology    Page : 498   Edition : 12,
A Route of administration in pharmacology and toxicology is the path by which a drug, fluid, poison, or other substance is taken into the body. Routes of administration are generally classified by the location at which the substance is applied. Common examples include oral and intravenous administration.

  ►  Route of administration : Oral,
Reference :-   Book : Martindale    Page : 900   Edition : 37,

Dosing of Medicine differ in Adult & Pediatrics ↓


Adult Dose

S.No Ailment   Route   Dose Min   Dose Max   Unit   Dosage Form   Frequency   Additional Info
1 Parkinson’s disease Oral 1 mg Tablet o.d. In the USA, an initial daily dose of 500 micrograms is recommended for adjunctive therapy.

Ref :-  Book : Martindale    Page : 900   Edition : 37,




Pediatric Dose

S.No Ailment   Age Min   Age Max   Weight ( Kg ) Route   Dose Min   Dose Max   Unit   Dosage Form   Frequency  Additional Info  

Ref :- Book :
►  Side Effect : headache, flu-like syndrome, malaise, neck pain, angina pectoris, dyspepsia, anorexia, leucopenia, arthralgia, arthritis, Depression, vertigo, rhinitis, conjunctivitis, Skin rashes, melanoma, urinary urgency, Orthostatic hypotension, hallucinations, ,
Ref :-   Book : Martindale    Page : 900   Edition : 37,

►  Drug Interaction : Drug interaction of Rasagiline is with Monoamine Oxidase Inhibitors, ,  Ciprofloxacin ,
Ref :-   Book : Martindale    Page : 900   Edition : 37,


  ►    Mechanism of Drug Drug Interaction :  Rasagiline should not be given with other MAOIs because of the risk of non-selective MAO inhibition that may lead to hypertensive reactions. It is metabolised by the cytochrome P450 isoenzyme CYP1A2 and potent inhibitors of this enzyme such as ciprofloxacin may increase the plasma levels of rasagiline . Tobacco smoking induces hepatic metabolic enzymes and may decrease the plasma levels of rasagiline.,
Ref :-   Book : Martindale    Page : 900   Edition : 37,


►  Contraindication : hepatic impairment,
Ref :-   Book : Martindale    Page : 900   Edition : 37,
  ►  Mechanism of Action :   Rasagiline is an irreversible selective inhibitor of monoamine oxidase type B, an enzyme involved in the metabolic degradation of dopamine in the brain. It enhances the effects of levodopa and is used in the treatment of Parkinson’s disease, either alone or as an adjunct to levodopa therapy to reduce ‘end-ofdose’ fluctuations in response,
Ref :-   Book : Martindale    Page : 900   Edition : 37,

Pathway of Dietry Product


​   ► Act.Comp / Nutrient / Food / Herb as follows :- Fava beans i.e. bakla with same compound, Amur Cortree with same pathway, Bakuchi with same pathway, Licorice Root with same pathway, Babchi with same pathway, Ginkgo biloba with same pathway, Vinca with same pathway,

  ►  Pathway with its reference as follows :-
  • Fava beans rich in levo-dihydroxyphenylalanine(L-Dopa) the precursor of dopamine. --- (Mehran S.M., Mohseni. "Simultaneous Determination Of Levodopa And Carbidopa From Fava Bean, Green Peas And Green Beans By High Performance Liquid Gas Chromatography". JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH (2013): n. pag. Web. 10 Nov. 2016. )
  • Monoamine oxide inhibitor . --- (Mazzio, E. "High Throughput Screening To Identify Natural Human Monoamine Oxidase B Inhibitors". 27.6 (2013): 818-828. Web. 16 Nov. 2016. )
  • Monoamine oxide inhibitor . --- (Mazzio, E. "High Throughput Screening To Identify Natural Human Monoamine Oxidase B Inhibitors". 27.6 (2013): 818-828. Web. 16 Nov. 2016. )
  • Monoamine oxide inhibitor . --- (Mazzio, E. "High Throughput Screening To Identify Natural Human Monoamine Oxidase B Inhibitors". 27.6 (2013): 818-828. Web. 16 Nov. 2016. )
  • Monoamine oxide inhibitor . --- (Mazzio, E. "High Throughput Screening To Identify Natural Human Monoamine Oxidase B Inhibitors". 27.6 (2013): 818-828. Web. 16 Nov. 2016. )
  • Monoamine oxide inhibitor . --- (Rajput, Mithun. "Natural Monoamine Oxidase Inhibitors : A Review". Journal of Pharmacy Research 3.0974-6943 (2010): ),482-485. Print. )
  • Monoamine oxide inhibitor . --- ( Rajput, Mithun. "Natural Monoamine Oxidase Inhibitors : A Review". Journal of Pharmacy Research 3.0974-6943 (2010): ),482-485. Print. )

  •   ►  URL -- https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3708185/, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3521852/, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3521852, file:///C:/Users/dr.%20lonch/Downloads/MAO%20Inhibitors.pdf,


    Dietry Substance Interactions


    ​   ► This Medicine interact with :- NA



    ContraIndication Dietry Substance


    ​   ► This Medicine contraindicate with :- NA

    ►   Route of Elimination :   Renal, Hepatic (Metabolism), Faecal,
    Ref :-   Book : Martindale    Page : 900   Edition : 37,


    ►    Plasma Half-life :
      Min value :-   0.6 hours,    Max value :-   2 hours,
    Ref :-   Book : Martindale    Page : 900   Edition : 37,

    ►    Peak Plasma Concentration :   Min value :-   30 minutes,    Max value :-   1 hours,
    Ref :-   Book : Martindale    Page : 900   Edition : 37,